Taxotere (docetaxel)

DRUG4 trials

Sponsors

Seagen Inc., University of Arizona, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Conditions

Breast CancerCastrate Sensitive Prostate CancerEsophageal CancerGastric CancerHead and Neck CancerLung CancerMetastatic CancerOvarian Cancer

Phase 1

Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors

CompletedNCT01172028

University of ArizonaBreast Cancer, Esophageal Cancer, Gastric Cancer +4

Start: 2005-09-30End: 2014-07-31Updated: 2015-12-03

Phase 2

Study of SGN-15, Antibody-Drug Conjugate, to Treat Hormone Refractory Prostate Cancer

CompletedNCT00031187

Seagen Inc.Prostatic Neoplasms

Start: 2000-10-31End: 2003-07-31Target: 160Updated: 2011-10-24

Phase 3

A Clinical Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer

RecruitingNCT06296706

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Gastric Cancer

Start: 2024-02-27End: 2027-06-01Target: 630Updated: 2024-11-14

Unknown Phase

PSA Biochemical Response as Prognostic Factor in Metastatic Castration-Sensitive Prostate Cancer

RecruitingNCT06652607

Fondazione Policlinico Universitario Agostino Gemelli IRCCSCastrate Sensitive Prostate Cancer, Metastatic Cancer, Prostate Cancer

Start: 2024-12-20End: 2028-04-30Target: 152Updated: 2025-03-12

Related Papers

A phase I study of pemetrexed in combination with docetaxel in advanced solid tumor patients.

Journal of Clinical Oncology2014-05-20